Botulinum toxin injections for chronic sialorrhoea in children are effective regardless of the degree of neurological dysfunction: A single tertiary institution experience

详细信息    查看全文

• 作者：Murali Mahadevan^a ; ^{MuraliM@adhb.govt.nz" class="auth_mail" title="E-mail the corresponding author} ; Maayan Gruber^a ; Darin Bilish^a ; Kathryn Edwards^b ; David Davies-Payne^c ; Graeme van der Meer^a
• 关键词：Botox® ; Botulinum toxin type-A ; Drooling ; Sialorrhoea ; Submandibular glands ; Cerebral palsy
• 刊名：International Journal of Pediatric Otorhinolaryngology
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：88
• 期：Complete
• 页码：142-145
• 全文大小：185 K

文摘

To determine the effectiveness of submandibular salivary gland Botulinum Toxin Type-A (BTX-A) injection in the treatment of drooling in children with varying degrees of neurological dysfunction.

Methods

A retrospective review of pre- and post-procedure drooling frequency and severity scores of patients receiving BTX-A between January 2008 and January 2013. Stratification to different subgroups of neurological impairment was performed according to Gross Motor Function Classification System (GMFCS) score. Drooling severity was assessed using Thomas-Stonell and Greenberg symptom questionnaires administered at time of initial consultation and 3 months after treatment.

Results

48 sets of BTX-A injections in 26 patients with an average age of 9.45 years (range 7 months–18 years) were included in the study. Marked improvement in drooling was seen in 60.4% of patients, a marginal or brief improvement was seen in 20.8% and there was no improvement in 18.8%. No adverse events were reported following any of the BTX-A injections. BTX-A was safe and effective in the eight patients with pre-existing swallowing dysfunction. Subsequent drooling surgery was performed in 15 (57.7%) of the cohort, all 15 patients responded to BTX-A injections.

In patients with Cerebral Palsy, there was no correlation between the severity of the neurological dysfunction as measured by the Gross Motor Function Classification System (GMFCS) score and the response to BTX-A treatment.

Conclusions

Injection of BTX-A to the submandibular glands of children with neurological disorders is a safe procedure and results in a reduction in drooling in the majority of patients. Children with severe neurological dysfunction respond to BTX-A injections as effectively as their less impaired peers and the degree of response does not appear to be associated with the severity of neurological disability. BTX-A injection is a good initial procedure when drooling surgery is being considered.